BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 32151286)

  • 1. Molecular profiling of an osseous metastasis in glioblastoma during checkpoint inhibition: potential mechanisms of immune escape.
    Mohme M; Maire CL; Schliffke S; Joosse SA; Alawi M; Matschke J; Schüller U; Dierlamm J; Martens T; Pantel K; Riethdorf S; Lamszus K; Westphal M
    Acta Neuropathol Commun; 2020 Mar; 8(1):28. PubMed ID: 32151286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current advances in PD-1/PD-L1 axis-related tumour-infiltrating immune cells and therapeutic regimens in glioblastoma.
    Shu C; Li Q
    Crit Rev Oncol Hematol; 2020 Jul; 151():102965. PubMed ID: 32442903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spinal metastasis of glioblastoma multiforme before gliosarcomatous transformation: a case report.
    Hsu BH; Lee WH; Yang ST; Han CT; Tseng YY
    BMC Neurol; 2020 May; 20(1):178. PubMed ID: 32393192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extensive Leptomeningeal Intracranial and Spinal Metastases in a Patient with a Supratentorial Glioblastoma Multiforme, IDH-Wildtype.
    Schwartz C; Romagna A; Machegger L; Weiss L; Huemer F; Fastner G; Kleindienst W; Weis S; Greil R; Winkler PA
    World Neurosurg; 2018 Dec; 120():442-447. PubMed ID: 30253992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patient.
    Anghileri E; Di Ianni N; Paterra R; Langella T; Zhao J; Eoli M; Patanè M; Pollo B; Cuccarini V; Iavarone A; Rabadan R; Finocchiaro G; Pellegatta S
    Cancer Immunol Immunother; 2021 Mar; 70(3):831-842. PubMed ID: 33140187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local Targeting of NAD
    Li M; Kirtane AR; Kiyokawa J; Nagashima H; Lopes A; Tirmizi ZA; Lee CK; Traverso G; Cahill DP; Wakimoto H
    Cancer Res; 2020 Nov; 80(22):5024-5034. PubMed ID: 32998997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Widely metastatic glioblastoma with BRCA1 and ARID1A mutations: a case report.
    Umphlett M; Shea S; Tome-Garcia J; Zhang Y; Hormigo A; Fowkes M; Tsankova NM; Yong RL
    BMC Cancer; 2020 Jan; 20(1):47. PubMed ID: 31959133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor associated CD70 expression is involved in promoting tumor migration and macrophage infiltration in GBM.
    Ge H; Mu L; Jin L; Yang C; Chang YE; Long Y; DeLeon G; Deleyrolle L; Mitchell DA; Kubilis PS; Lu D; Qi J; Gu Y; Lin Z; Huang J
    Int J Cancer; 2017 Oct; 141(7):1434-1444. PubMed ID: 28612394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma.
    Lee KS; Lee K; Yun S; Moon S; Park Y; Han JH; Kim CY; Lee HS; Choe G
    J Neurooncol; 2018 Feb; 136(3):453-461. PubMed ID: 29147863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions.
    Maghrouni A; Givari M; Jalili-Nik M; Mollazadeh H; Bibak B; Sadeghi MM; Afshari AR; Johnston TP; Sahebkar A
    Int Immunopharmacol; 2021 Apr; 93():107403. PubMed ID: 33581502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid tumor recurrence in a novel murine GBM surgical model is associated with Akt/PD-L1/vimentin signaling.
    Liu F; Xu XH; Li CY; Zhang TT; Yin SL; Liu GQ; Hu F; Yu SB; Chen XQ
    Biochem Biophys Res Commun; 2021 Sep; 569():1-9. PubMed ID: 34216991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination immunotherapy strategies for glioblastoma.
    Chan HY; Choi J; Jackson C; Lim M
    J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Inhibitor-induced Reinvigoration of Tumor-infiltrating CD8
    Park J; Kwon M; Kim KH; Kim TS; Hong SH; Kim CG; Kang SG; Moon JH; Kim EH; Park SH; Chang JH; Shin EC
    Clin Cancer Res; 2019 Apr; 25(8):2549-2559. PubMed ID: 30659023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series.
    Chamberlain MC; Kim BT
    J Neurooncol; 2017 Jul; 133(3):561-569. PubMed ID: 28500559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infratentorial Glioblastoma Metastasis to Bone.
    Ricard JA; Cramer SW; Charles R; Gil Tommee C; Le A; Bell WR; Chen CC; Flanagan ME
    World Neurosurg; 2019 Nov; 131():90-94. PubMed ID: 31356980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes.
    Mohme M; Schliffke S; Maire CL; Rünger A; Glau L; Mende KC; Matschke J; Gehbauer C; Akyüz N; Zapf S; Holz M; Schaper M; Martens T; Schmidt NO; Peine S; Westphal M; Binder M; Tolosa E; Lamszus K
    Clin Cancer Res; 2018 Sep; 24(17):4187-4200. PubMed ID: 29444930
    [No Abstract]   [Full Text] [Related]  

  • 17. Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma.
    Iorgulescu JB; Gokhale PC; Speranza MC; Eschle BK; Poitras MJ; Wilkens MK; Soroko KM; Chhoeu C; Knott A; Gao Y; Lim-Fat MJ; Baker GJ; Bonal DM; Nguyen QD; Grant GRL; Ligon KL; Sorger PK; Chiocca EA; Anderson AC; Kirschmeier PT; Sharpe AH; Freeman GJ; Reardon DA
    Clin Cancer Res; 2021 Jan; 27(1):276-287. PubMed ID: 33239433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome.
    Favero F; McGranahan N; Salm M; Birkbak NJ; Sanborn JZ; Benz SC; Becq J; Peden JF; Kingsbury Z; Grocok RJ; Humphray S; Bentley D; Spencer-Dene B; Gutteridge A; Brada M; Roger S; Dietrich PY; Forshew T; Gerlinger M; Rowan A; Stamp G; Eklund AC; Szallasi Z; Swanton C
    Ann Oncol; 2015 May; 26(5):880-887. PubMed ID: 25732040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma.
    Tong L; Li J; Li Q; Wang X; Medikonda R; Zhao T; Li T; Ma H; Yi L; Liu P; Xie Y; Choi J; Yu S; Lin Y; Dong J; Huang Q; Jin X; Lim M; Yang X
    Theranostics; 2020; 10(13):5943-5956. PubMed ID: 32483429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges to Successful Implementation of the Immune Checkpoint Inhibitors for Treatment of Glioblastoma.
    Sanders S; Debinski W
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32316096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.